Market Access Views & Analysis

Views & Analysis

Market Access

Why the Novo Nordisk Foundation is betting big on stem cells

One area where the Novo Nordisk Foundation has invested quite heavily is in cell therapy, especially stem cell research.

Patients

Pharmacy First: Why technology is necessary for safeguarding...

The challenges facing UK healthcare are abundantly clear.

Market Access

AMR could kill 10M in 2050, but there’s little profit in sto...

Last month, the Novo Nordisk Foundation welcomed a group of journalists<

Market Access

New NICE Advice service

Leela Barham digs into what’s publicly available on the success of NICE Advice just as the institute launched a refreshed offer to life sciences companies.

Market Access

Supply chains and the importance of transparency

The pandemic revealed that global supply chains for the pharma industry are more fragile than expected.

Market Access

NICE to consult on inflation-busting fee increases

NICE ran a webinar on 2nd November, setting out – ahead of a formal consultation due to open on 21s

Why the Novo Nordisk Foundation is betting big on stem cells

Pharmacy First: Why technology is necessary for safeguarding...

AMR could kill 10M in 2050, but there’s little profit in sto...

New NICE Advice service

Supply chains and the importance of transparency

NICE to consult on inflation-busting fee increases

Ambrosia's sweet $100m round, and other biofinancings

Using AI-driven synthetic personas to take your insights fur...

Views & Analysis

Editor's Picks